" class="no-js "lang="en-US"> Capsida Biotherapeutics Archives - Medtech Alert
Friday, March 29, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer

Capsida Biotherapeutics today announced the appointment of Susan Catalano as the company’s Chief Scientific Officer (CSO). Dr. […]

AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need

AbbVie and Capsida Biotherapeutics today announced an expanded strategic collaboration to develop genetic medicines for […]

Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing

Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more